Home › Funds › PERCEPTIVE ADVISORS LLC › XFOR
PERCEPTIVE ADVISORS LLC position in XFOR
X4 PHARMACEUTICALS INC · Health Care
PERCEPTIVE ADVISORS LLC reported holding 7,933,491 shares of XFOR (X4 PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$37.0M, representing 0.59% of its reported portfolio and ranking #39 among its reported holdings. PERCEPTIVE ADVISORS LLC has disclosed XFOR holdings in 8 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How PERCEPTIVE ADVISORS LLC's XFOR position evolved
PERCEPTIVE ADVISORS LLC first disclosed a stake in XFOR in Q3 2023 at 3,545,454 shares (US$3.9M). The position peaked in Q2 2026 at 7,933,491 shares, worth US$37.0M. Across 8 filings, PERCEPTIVE ADVISORS LLC increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 4 time(s). The most recent filing (Q2 2026) shows 7,933,491 shares valued at US$37.0M — an increase of 1,195,843 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 3.55M | $3.86M | New |
| Q4 2023 | 3.55M | $2.97M | Hold |
| Q1 2024 | 3.55M | $4.93M | Hold |
| Q2 2024 | 3.55M | $2.06M | Hold |
| Q3 2024 | 3.55M | $2.37M | Hold |
| Q4 2025 | 6.31M | $25.26M | New |
| Q1 2026 | 6.74M | $27.83M | Add |
| Q2 2026 | 7.93M | $37.05M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About XFOR and 13F data
XFOR (X4 PHARMACEUTICALS INC) is a Health Care company. 40 other funds we track also report a position in XFOR — the largest reported positions include Bain Capital Life Sciences Investors, LLC (US$37.2M), Saturn V Capital Management LP (US$32.6M), Empery Asset Management, LP (US$32.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding XFOR
- Bain Capital Life Sciences Investors, LLC 7.97M sh · $37.21M · Q2 2026
- Saturn V Capital Management LP 6.97M sh · $32.57M · Q2 2026
- Empery Asset Management, LP 6.93M sh · $32.37M · Q2 2026
- Deep Track Capital, LP 5.88M sh · $27.45M · Q2 2026
- Kalehua Capital Management LLC 3.72M sh · $17.39M · Q2 2026
- NEA Management Company, LLC 3.23M sh · $15.10M · Q2 2026
- Rosalind Advisors, Inc. 3.21M sh · $15.01M · Q2 2026
- Trails Edge Capital Partners, LP 2.57M sh · $12.01M · Q2 2026
- BVF INC/IL 2.23M sh · $10.43M · Q2 2026
- Venrock Adviser, LLC 1.93M sh · $9.03M · Q2 2026
- Samsara BioCapital, LLC 1.40M sh · $6.52M · Q2 2026
- Verdad Advisers, LP 352.09K sh · $1.64M · Q2 2026
More on PERCEPTIVE ADVISORS LLC
FAQ
How long has PERCEPTIVE ADVISORS LLC held XFOR?
PERCEPTIVE ADVISORS LLC has disclosed XFOR holdings in 8 of the last 12 reported quarters, going back to Q3 2023.
What is PERCEPTIVE ADVISORS LLC's current position in XFOR?
As of Q2 2026, PERCEPTIVE ADVISORS LLC holds 7.93M shares of XFOR (X4 PHARMACEUTICALS INC), valued at $37.05M, representing 0.59% of its reported portfolio and ranking #39.
Has PERCEPTIVE ADVISORS LLC been buying or selling XFOR?
In the latest 13F filing (Q2 2026), PERCEPTIVE ADVISORS LLC increased its position in XFOR. The position peaked in Q2 2026 at 7.93M shares.
Which other funds hold XFOR?
Other major institutional holders of XFOR include Bain Capital Life Sciences Investors, LLC, Saturn V Capital Management LP, Empery Asset Management, LP, among 40 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.